Clofibrate

Jump to: navigation, search
Clofibrate
Clofibrate.svg
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: B1
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • US: Discontinued
Pharmacokinetic data
Protein bindingVariable, 92–97% at therapeutic concentrations
MetabolismHydrolyzed to clofibric acid; hepatic glucuronidation
Elimination half-lifeHighly variable; average 18–22 hours. Prolonged in renal failure
ExcretionRenal, 95 to 99%
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC12H15ClO3
Molar mass242.698 g/mol
3D model (JSmol)
Boiling point148 °C (298.4 °F)
  (verify)

WikiDoc Resources for Clofibrate

Articles

Most recent articles on Clofibrate

Most cited articles on Clofibrate

Review articles on Clofibrate

Articles on Clofibrate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Clofibrate

Images of Clofibrate

Photos of Clofibrate

Podcasts & MP3s on Clofibrate

Videos on Clofibrate

Evidence Based Medicine

Cochrane Collaboration on Clofibrate

Bandolier on Clofibrate

TRIP on Clofibrate

Clinical Trials

Ongoing Trials on Clofibrate at Clinical Trials.gov

Trial results on Clofibrate

Clinical Trials on Clofibrate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Clofibrate

NICE Guidance on Clofibrate

NHS PRODIGY Guidance

FDA on Clofibrate

CDC on Clofibrate

Books

Books on Clofibrate

News

Clofibrate in the news

Be alerted to news on Clofibrate

News trends on Clofibrate

Commentary

Blogs on Clofibrate

Definitions

Definitions of Clofibrate

Patient Resources / Community

Patient resources on Clofibrate

Discussion groups on Clofibrate

Patient Handouts on Clofibrate

Directions to Hospitals Treating Clofibrate

Risk calculators and risk factors for Clofibrate

Healthcare Provider Resources

Symptoms of Clofibrate

Causes & Risk Factors for Clofibrate

Diagnostic studies for Clofibrate

Treatment of Clofibrate

Continuing Medical Education (CME)

CME Programs on Clofibrate

International

Clofibrate en Espanol

Clofibrate en Francais

Business

Clofibrate in the Marketplace

Patents on Clofibrate

Experimental / Informatics

List of terms related to Clofibrate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Clofibrate (tradename Atromid-S) is an organic compound. It is marketed as a fibrate. It is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well.

Complications and controversies

It can induce SIADH, syndrome of inappropriate secretion of antidiuretic hormone ADH (vasopressin).

The World Health Organization Cooperative Trial on Primary Prevention of Ischaemic Heart Disease using clofibrate to lower serum cholesterol observed excess mortality in the clofibrate-treated group despite successful cholesterol lowering (47% more deaths during treatment with clofibrate and 5% after treatment with clofibrate) than the non-treated high cholesterol group. These deaths were due to a wide variety of causes other than heart disease, and remain "unexplained".[1]

Clofibrate was discontinued in 2002 due to adverse affects.

Synthesis

Clofibrate synthesis.[2]

References

  1. "WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators". Lancet. 2 (8403): 600–4. September 1984. PMID 6147641.
  2. http://drugsynthesis.blogspot.co.uk/2012/04/laboratory-synthesis-of-clofibrate.html

Linked-in.jpg